Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jason Kropp"'
Autor:
Pete Weber, Fuxin Shi, John Soglia, John Keilty, Heather Wolff, Ryan McCarthy, Jason Kropp, Vissia Viglietta, Yong Ren, Hu Qi-Ying
Publikováno v:
Investigational New Drugs
SummaryCisplatin is a widely used chemotherapy for the treatment of certain solid tumors. Ototoxicity and subsequent permanent hearing loss remain a serious dose-limiting side effect associated with cisplatin treatment. To date, no therapies have bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b073d057d72a2692bbc65bd88ddba9c3
https://doi.org/10.1007/s10637-020-00918-1
https://doi.org/10.1007/s10637-020-00918-1
Autor:
John Lee, Roger H. Pak, Louis Grenier, Vince Ammoscato, Michael Curtis, Kaiming Li, John Henderson, Matthew Campbell, Denise Mayes, Jason Kropp, Natalie Goltz, Bennett Carter, Johan Sebastian Basuki, Bradley Maurer, Gary Baker, James R. Wright, David Rusch, Rebecca Ahn, Brian C. Austad, Kris Depew, Joseph Helble, Jie Ge, Jason J. Piotrowski, Marlene R. Booth, Julian Adams, Mark Douglas, Steven G. Wong, Laila Kott, James R. Porter, Geoff E. Sylvester, Dumitru Ionescu, Jennifer R. Porter, Brendan Arsenault
Publikováno v:
Drug Development Research. 71:429-438
IPI-504 (retaspimycin hydrochloride) is an Hsp90 inhibitor that is the subject of multiple clinical trials for the treatment of cancer. IPI-504 is an aqueous soluble (>200 mg/ml) hydroquinone hydrochloride salt of 17-(allylamino)-17-demethoxygeldanam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1542e76e86b5ffd5bfe160834ae9e695
https://doi.org/10.1002/ddr.20383
https://doi.org/10.1002/ddr.20383